Dr Markson completed his PhD in molecular biology at the MRC Human Genome Mapping Project and Cambridge Institute for Medical Research, University of Cambridge, UK.
Subsequently he joined Cambridge Consultants and worked on multiple deals where he was involved in the commercial and technical due diligence of biopharma/biotech companies. In 2010 he became part of the commercial operations team at Nycomed in Zurich, where he responsible for technical evaluation and valuation of in-licensing deals, contributed to a major biotech acquisition in China, and was heavily involved in the sell-side due diligence resulting in the sale to Takeda for EUR 9.6 Bn. After the sale of Nycomed to Takeda, he joined Gambro where he was responsible for corporate strategy development and implementation, and heavily involved in the sell-side due diligence and sale to Baxter for USD 4 Bn, as well as Master Planner for the subsequent integration. In 2014, Dr Markson joined BSN medical as Head of Strategic Planning and Business Development, where he was responsible for corporate strategy development and implementation, business development, business intelligence, and heavily involved in the sell-side due diligence and sale to SCA for EUR 2.74 Bn in 2017.
Dr Markson co-founded E3 Life AG, a lifescience investment boutique, in Zug, Switzerland in 2017. Since its inception, E3 Life has worked on multiple M&A processes in biotech and medtech, and is currently engaged in several lifescience investments together with large institutional investors. E3 Life has a special interest in clinical oncology, and how digital and Al technologies can accelerate cancer therapeutic development and application. Dr Markson is a co-founder of Dayton Therapeutics AG.